Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033657 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
A Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 20
- Study locations
NCT00033657: Completed Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Eastern Cooperative Oncology Group.
NCT00033657 is a Phase 2 study of Gastric Cancer and Esophageal Cancer that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 97 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033657, a Phase 2 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy before and after surgery may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of combining radiation therapy with two different chemotherapy regimens before and after surgery in treating patients who have esophageal cancer.
Primary Outcome
A patient would have achieved a pathologic complete response if no histopathological evidence of residual tumor is found in the resected esophageal specimen and nodal tissue.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- DRUG irinotecan hydrochloride
Study Locations (20)
Illinois
- Veterans Affairs Medical Center - Lakeside Chicago - Chicago
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
- CCOP - Carle Cancer Center - Urbana
Minnesota
- Mayo Clinic Cancer Center - Rochester
- CCOP - Metro-Minnesota - Saint Louis Park
- St. Joseph's Hospital - Saint Paul
Ohio
- Ireland Cancer Center - Cleveland
- MetroHealth's Cancer Care Center at MetroHealth Medical Center - Cleveland
- CCOP - Toledo Community Hospital - Toledo
Pennsylvania
- CCOP - MainLine Health - Wynnewood
- Lankenau Cancer Center at Lankenau Hospital - Wynnewood
Colorado
- CCOP - Colorado Cancer Research Program, Incorporated - Denver
Delaware
- CCOP - Christiana Care Health Services - Newark
Florida
- Shands Cancer Center at the University of Florida Health Science Center - Gainesville
Iowa
- CCOP - Iowa Oncology Research Association - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2002-08-15 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
What the finished NCT00033657 record still lists
NCT00033657 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT00033657 names 20 study sites across 13 states, led by Illinois, Minnesota, Ohio.
Frequently Asked Questions
What is clinical trial NCT00033657 about?
NCT00033657 is a clinical study titled "Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy before and after surgery may kill more tumor cells. PURPOSE: Randomi...
What is the current status of trial NCT00033657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2002-08-15. Estimated completion is 2009-10.
What conditions does trial NCT00033657 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT00033657?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00033657?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00033657 being conducted?
This trial has 20 study locations across Colorado, Delaware, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00033657's enrollment target sits among peer trials
97 91st of 153 higher than 62 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI